Business Wire

Smiths Detection launches compact CT checkpoint X-ray

28.2.2023 10:00:00 EET | Business Wire | Press release

Share

Smiths Detection, a global leader in threat detection and security screening technologies, today announces that it has launched the HI-SCAN 6040 CTiX Model S, a smaller footprint version of its successful, security operator preferred, Computed Tomography (CT) passenger checkpoint scanner.

This new model, which is 20cm narrower and 350kg lighter than the HI-SCAN 6040 CTiX, can be easily integrated into existing and new airport or critical infrastructure checkpoints. Both models of the HI-SCAN 6040 CTiX feature industry leading image quality and low levels of energy consumption, a belt speed of 0.2m/s, which is 30% higher than other CT X-ray scanners, alongside low noise levels and zero vibration, improving the checkpoint experience for both passengers and security operators.

The HI-SCAN 6040 CTiX Model S harnesses the power of CT X-ray scanning eliminating the need to remove electronic devices, liquids and gels from hand luggage by producing 3D volumetric images, reducing the number of trays and speeding up the security screening process. The new Model S also features the original model’s award winning operator interface.

The HI-SCAN 6040 CTiX Model S can be seamlessly integrated alongside both Smiths Detection and third-party technology, supporting the development of open architecture solutions. It can be further enhanced with Smiths Detection’s iCMORE automated object recognition software which allows for automated detection of an ever-expanding list of prohibited items, improving security outcomes and efficiency. While the latest data security features and controls ensure customer data and assets are well protected from cyber-attacks.

Philo Daniel, Global Director Aviation, Smiths Detection said: “With over 700 units sold globally, the market leading HI-SCAN 6040 CTiX delivers the very best passenger baggage security solution, and we are delighted to further enhance our product portfolio with this new launch. We have developed a more streamlined checkpoint scanner, which can fit into checkpoints with size and layout limitations, that improves energy efficiency, the screening process, security outcomes and passenger experience.”

The HI-SCAN 6040 CTiX Model S is ECAC EDS CB C3 approved in Europe, with further local approvals to follow.

ENDS

About Smiths Detection:

Smiths Detection is a global leader in threat detection and screening technologies for aviation, ports and borders, urban security and defence. With more than 70 years of field-tested experience, Smiths Detection deliver the solutions needed to protect society from the threat and illegal passage of explosives, prohibited weapons, contraband, toxic chemicals, biological agents, and narcotics – helping make the world a safer place.

For more information visit http://www.smithsdetection.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

FTI Consulting:
Tom Hufton/Harriet Jackson/Ffion Dash
sc.smithsdetection@fticonsulting.com
+44 (0)20 3727 1000

Smiths Detection:
Sophie Mills, Head of Corporate Communications
sophie.mills@smithsdetection.com
+ 44 (0)73 8423 6474

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye